Regulate Drug Release Research Articles

Enhancing the Efficacy of Active Pharmaceutical Ingredients in Medicinal Plants through Nanoformulations: A Promising Field.

This article explores the emerging field of nanomedicine as a drug delivery system, aimed at enhancing the therapeutic efficacy of active pharmaceutical ingredients in medicinal plants. The traditional methods of applying medicinal plants present several limitations, such as low bioavailability, poor solubility, challenges in accurately controlling drug dosage, and inadequate targeting. Nanoformulations represent an innovative approach in drug preparation that employs nanotechnology to produce nanoscale particles or carriers, which are designed to overcome these limitations. Nanoformulations offer distinct advantages, significantly enhancing the solubility and bioavailability of drugs, particularly for the poorly soluble components of medicinal plants. These formulations effectively enhance solubility, thereby facilitating better absorption and utilization by the human body, which in turn improves drug efficacy. Furthermore, nanomedicine enables targeted drug delivery, ensuring precise administration to the lesion site and minimizing side effects on healthy tissues. Additionally, nanoformulations can regulate drug release rates, extend the duration of therapeutic action, and enhance the stability of treatment effects. However, nanoformulations present certain limitations and potential risks; their stability and safety require further investigation, particularly regarding the potential toxicity with long-term use. Nevertheless, nanomaterials demonstrate substantial potential in augmenting the efficacy of active pharmaceutical ingredients in medicinal plants, offering novel approaches and methodologies for their development and application.

Betulin-NLC-hydrogel for the Treatment of Psoriasis-like Skin Inflammation: Optimization, Characterisation, and In vitro and In vivo Evaluation.

Psoriasis is a chronic inflammatory skin disorder that poses significant challenges regarding effective and targeted drug delivery. Bioactive substances like betulin have shown tremendous utility in treating these conditions; however, they pose limited utility owing to their physicochemical characteristics. Here, we aimed to develop a novel topical dosage form for treating psoriasis, utilising betulin-loaded solid lipid nanoparticles (NLCs) incorporated into a hydrogel matrix. The optimization of the formulation was meticulously conducted using a design of experiments methodology, and its diverse physicochemical attributes were thoroughly examined. Evaluating betulin's in vitro release pattern from the NLC-hydrogel demonstrated consistent and regulated drug release properties. Additionally, the formulation demonstrated improved skin penetration abilities as determined by in vitro skin permeation experiments employing Franz diffusion cells- furthermore, the therapeutic effectiveness of the betulin-NLC-hydrogel was assessed by an in vivo experiment carried out using an imiquimod-induced psoriasis-like skin inflammation model in BALB/c female mice. The NLCs exhibited a pH of 5.67±0.86, particle size of 148.16±12.66 nm, and zeta potential of -22.84±2.37 mV, ensuring stability and suitability for topical use. The gel, with a pH of 6.05±0.43 and viscosity of 17550±120 cPs, showed enhanced skin hydration and lipid restoration. Drug release studies indicated a slower release from NLCs and gel, improving skin retention. Stability tests revealed that the formulations were stable at room temperature but not at elevated temperatures. The in vitro safety profile of the formulation revealed no significant adverse effects on HaCaT cell lines. The NLC gel demonstrated significant anti-psoriatic activity, reducing inflammation and cytokine levels. The betulin-NLC-hydrogel formulation exhibited promising characteristics for the topical treatment of psoriasis, showcasing optimised drug delivery, sustained release, and notable therapeutic efficacy. The findings from this study provide a foundation for the potential clinical translation of this innovative topical dosage form for improved psoriasis management.

Physicochemical Stimulus-Responsive Systems Targeted with Antibody Derivatives.

The application of monoclonal antibodies and antibody fragments with the advent of recombinant antibody technology has made notable progress in clinical trials to provide a regulated drug release and extra targeting to the special conditions in the function site. Modification of antibodies has facilitated using mAbs and antibody fragments in numerous models of therapeutic and detection utilizations, such as stimuli-responsive systems. Antibodies and antibody derivatives conjugated with diverse stimuli-responsive materials have been constructed for drug delivery in response to a wide range of endogenous (electric, magnetic, light, radiation, ultrasound) and exogenous (temperature, pH, redox potential, enzymes) stimuli. In this report, we highlighted the recent progress on antibody-conjugated stimuli-responsive and dual/multi-responsive systems that affect modern medicine by improving a multitude of diagnostic and treatment strategies.

BIOSYNTHESIZE NANOPARTICLES AS ADVANCED NANOCARRIERS FOR TARGETED THERAPEUTIC INTERVENTIONS IN DISEASE MANAGEMENT

Biosynthesized nanoparticles have emerged as cutting-edge nanocarriers for targeted therapeutic interventions in illness management, transforming medication delivery and treatment techniques. These nanoparticles provide a biocompatible and sustainable substitute for conventional synthetic processes since they are made utilizing biological systems including fungi, bacteria, and plants. They are perfect candidates for precision medicine because of their innate capacity to lower toxicity and increase bioavailability. Because of their distinct surface characteristics, biosynthesized nanoparticles are easily functionalized with therapeutic drugs, allowing for targeted distribution to sick cells or certain organs while reducing off-target effects. Additionally, the large surface area-to-volume ratio and nanoscale size promote better cellular absorption and regulated drug release, enhancing therapeutic efficacy. These nanoparticles' natural origin lowers their immunogenicity and adverse response risk, which enhances patient outcomes even more. Biosynthesized nanoparticles have demonstrated great promise in cancer therapy, including the ability to target tumor cells specifically, carry chemotherapy medications, and even combine with imaging agents for theragnostic uses. They also show promise in improving therapy specificity and lowering adverse effects in other diseases like infectious diseases, cardiovascular ailments, and neurological disorders. This study covers the developments in biosynthesized nanoparticles as nanocarriers, highlighting their importance in altering illness management through tailored therapeutics while evaluating the limitations and future prospects for their clinical translation.

Inhibitory impact of a mesoporous silica nanoparticle-based drug delivery system on Porphyromonas gingivalis-induced bone resorption

Controlling and reducing plaque formation plays a pivotal role in preventing and treating periodontal disease, often utilizing antibacterial drugs to enhance therapeutic outcomes. Mesoporous silica nanoparticles (MSN), an FDA-approved inorganic nanomaterial, possess robust physical and chemical properties, such as adjustable pore size and pore capacity, easy surface modification, and high biosafety. Numerous studies have exploited MSN to regulate drug release and facilitate targeted delivery. This study aimed to synthesize an MSN-tetracycline (MSN-TC) complex and investigate its inhibitory potential on Porphyromonas gingivalis (P. gingivalis)-induced bone resorption. The antibacterial efficacy of MSN-TC was evaluated through bacterial culture experiments. A P. gingivalis-induced bone resorption model was constructed by subcutaneously injecting P. gingivalis around the cranial bone of rats. Micro-computed tomography was employed to assess the inhibitory impact of MSN and MSN-TC on bone resorption. Furthermore, the influence of MSN and MSN-TC on osteoclast differentiation was examined in vitro. The MSN exhibited optimal pore size and particle dimensions for effective loading and gradual release of TC. MSN-TC demonstrated significant bacteriostatic activity against P. gingivalis. MSN-TC-treated rats showed significantly reduced cranial bone tissue destruction compared to MSN or TC-treated rats. Additionally, both MSN and MSN-TC exhibited inhibitory effects on the receptor activator of nuclear factor kappa-Β ligand-mediated osteoclast differentiation. The MSN-TC complex synthesized in this study demonstrated dual efficacy by exerting antibacterial effects on P. gingivalis and by resisting osteoclast differentiation, thereby mitigating bone resorption induced by P. gingivalis.Graphical

Construction of anticancer drug incorporated aptamer-functionalized cationic β-lactoglobulin: induction of cell cycle arrest and apoptosis in colorectal cancer

Nanoscale drug delivery systems that are both multifunctional and targeted have been developed using proteins as a basis, thanks to their attractive biomacromolecule properties. A novel nanocarrier, aptamer (AS1411)-conjugated β-lactoglobulin/poly-l-lysine (BLG/Ap/PL) nanoparticles, was developed in this study. To this unique formulation, the as-prepared nanocarrier blends the distinctive features of an aptamer as a chemotherapeutic targeting agent with those of protein nanocarriers. By loading cabazitaxel (CTX) onto the nanocarriers, the therapeutic potential of BLG/Ap/PL could be demonstrated. The CTX-loaded BLG/Ap/PL (CTX@BLG/Ap/PL) showed a regulated drug release profile in an acidic milieu, which could improve therapeutic efficacy in cancer cells and have a high drug encapsulation efficacy of up to 93%. However, compared to free CTX, CTX@BLG/Ap/PL killed colorectal HCT116 cancer cells with a higher efficacy at 24 and 48 h. Further investigation confirms the apoptosis by acridine orange and ethidium bromide (AO/EB), and DAPI staining confirms the morphological changes, chromatin condensation, and membrane blebbing in the treated cell through flow cytometry displayed the release of higher percentages of apoptosis. Cell cycle analysis revealed that CTX@BLG/Ap/PL induced sub-G1 and G2/M phase (apoptosis) at 24 and 48 h. Annexin V/propidium iodide (PI) flow cytometry analysis confirmed that CTX@BLG/Ap/PL induces apoptosis in HCT116 cells. Overall, this study proved that CTX@BLG/Ap/PL had several advantages over free chemotherapeutic drugs and showed promise as a solution to the clinical problems associated with targeted antitumor drug delivery systems.

Progress in Utilizing Chitosan-Based Nanoparticles for Pulmonary Drug Administration

The escalating prevalence of respiratory ailments poses a significant global public health challenge, ranking among the primary causes of mortality worldwide. Notably, diseases such as asthma, chronic obstructive pulmonary disease, pneumonia, cystic fibrosis, and lung cancer, alongside the emergence of respiratory diseases, notably those induced by the coronavirus family, have contributed substantially to global fatalities in the past two decades. Consequently, numerous studies have been undertaken to enhance the effectiveness of therapeutic interventions against these diseases, with a particular emphasis on nanomedicine-driven pulmonary drug delivery. As a result, the development of nanocarriers has emerged as a promising avenue to surmount the constraints associated with traditional therapies, aiming to elevate drug bioavailability at the intended site while minimizing undesired side effects. Within this domain, nanoparticles fashioned from chitosan (CS) exhibit distinct advantages over alternative nanocarriers owing to the inherent biological properties of chitosan, including its anti-inflammatory, antimicrobial, and mucoadhesive attributes. Furthermore, CS nanoparticles have demonstrated the potential to augment drug stability, extend the duration of action, refine drug targeting, regulate drug release kinetics, optimize the dissolution of poorly soluble drugs, and enhance the cell membrane permeability of hydrophobic drugs. These unique properties position CS nanoparticles as a promising candidate for optimizing drug performance following pulmonary administration. Consequently, this review endeavors to elucidate the potential of chitosan nanoparticles in the realm of pulmonary drug delivery, shedding light on how their intrinsic biological characteristics can ameliorate the treatment landscape of pulmonary diseases. Emphasis is placed on delineating the synergistic interplay between chitosan nanoparticles and the encapsulated drug, thereby offering insights into the prospective advancements in treating respiratory ailments.

Controlled Release of Curcumin and Hypocrellin A from Electrospun Poly(l-Lactic Acid)/Silk Fibroin Nanofibers for Enhanced Cancer Cell Inhibition.

Nanofibers have emerged as a highly effective method for drug delivery, attributed to their remarkable porosity and ability to regulate drug release rates while minimizing toxicity and side effects. In this study, we successfully loaded the natural anticancer drugs curcumin (CUR) and hypocrellin A (HA) into pure poly(l-lactic acid) (PLLA) and PLLA-silk protein (PS) composite nanofibers through electrospinning technology. This result was confirmed through comprehensive analysis involving SEM, FTIR, XRD, DSC, TG, zeta potential, and pH stability analysis. The encapsulation efficiency of all samples exceeded 85%, demonstrating the effectiveness of the loading process. Additionally, the drug release doses were significantly higher in the composites compared to pure PLLA, owing to the enhanced crystallinity and stability of the silk proteins. Importantly, the composite nanofibers exhibited excellent pH stability in physiological and acidic environments. Furthermore, the drug-loaded composite nanofibers displayed strong inhibitory effects on cancer cells, with approximately 28% (HA) and 37% (CUR) inhibition of cell growth and differentiation within 72 h, while showing minimal impact on normal cells. This research highlights the potential for controlling drug release through the manipulation of fiber diameter and crystallinity, paving the way for wider applications of electrospun green nanomaterials in the field of medicine.

Formulation and Evaluation of Bilayered Floating Tablets of Aceclofenac

The objective of this study was to create and assess homogeneous bilayered floating tablets of aceclofenac in order to increase the drug's bioavailability and prolong its stomach release. One of the nonsteroidal anti-inflammatory drugs (NSAID) common side effects is poor solubility and minimal stomach retention, which makes it difficult to treat effectively. As matrix-forming polymers, ten formulations (F1–F10) were made with different amounts of HPMC K15 and additional excipients. Physical properties, buoyancy, in vitro drug release, and kinetic modelling were evaluated for each formulation. With a floating lag time of less than one minute and buoyancy maintained for more than 12 hours, Formulation 5 (F5) showed the most promising findings. With 97.01% of aceclofenac released over 12 hours, it showed a regulated drug release pattern that followed the Korsmeyer-Peppas release model well (R2 = 0.9242). Pre-compression and post-compression values for the optimised formulation F5 were adequate, suggesting good flow characteristics and tablet integrity. FTIR spectroscopy was used to verify the drug-excipient compatibility, guaranteeing stability and the lack of interactions. According to these results, aceclofenac's homogenous bilayered floating tablets, specifically formulation F5, may be able to improve gastric retention time and offer a sustained release profile. This could mean that the medication can be used to treat chronic inflammatory conditions more effectively and with better patient compliance. Keywords: gastric retention, bioavailability, drug excipient compatibility.

Matrix metalloproteinase-responsive hydrogels with tunable retention for on-demand therapy of inflammatory bowel disease

Therapeutic options for addressing inflammatory bowel disease (IBD) include the administration of an enema to reduce intestinal inflammation and alleviate associated symptoms. However, uncontrollable retention of enemas in the intestinal tract has posed a long-term challenge for improving their therapeutic efficacy and safety. Herein we have developed a protease-labile hydrogel system as an on-demand enema vehicle with tunable degradation and drug release rates in response to varying matrix metalloproteinase-9 (MMP-9) expression. The system, composed of three tailored hydrogel networks, is crosslinked by poly (ethylene glycol) (PEG) with 2-, 4- and 8-arms through dynamic hydrazone bonds to confer injectability and generate varying network connectivity. The retention time of the hydrogels can be tuned from 12 to 36 h in the intestine due to their different degradation behaviors induced by MMP-9. The drug-releasing rate of the hydrogels can be controlled from 0.0003 mg/h to 0.278 mg/h. In addition, injection of such hydrogels in vivo resulted in significant differences in therapeutic effects including MMP-9 consumption, colon tissue repair, reduced collagen deposition, and decreased macrophage cells, for treating a mouse model of acute colitis. Among them, GP-8/5-ASA exhibits the best performance. This study validates the effectiveness of the tailored design of hydrogel architecture in response to pathological microenvironment cues, representing a promising strategy for on-demand therapy of IBD. Statement of significanceThe uncontrollable retention of enemas at the delivery site poses a long-term challenge for improving therapeutic efficacy in IBD patients. MMP-9 is highly expressed in IBD and correlates with disease severity. Therefore, an MMP-9-responsive GP hydrogel system was developed as an enema by linking multi-armed PEG and gelatin through hydrazone bonds. This forms a dynamic hydrogel characterized by in situ gelation, injectability, enhanced bio-adhesion, biocompatibility, controlled retention time, and regulated drug release. GP hydrogels encapsulating 5-ASA significantly improved the intestinal phenotype of acute IBD and demonstrated notable therapeutic differences with increasing PEG arms. This method represents a promising on-demand IBD therapy strategy and provides insights into treating diseases of varying severities using endogenous stimulus-responsive drug delivery systems.

Regulating Drug Release Performance of Acid-Triggered Dimeric Prodrug-Based Drug Self-Delivery System by Altering Its Aggregation Structure.

Dimeric prodrugs have been investigated intensely as carrier-free drug self-delivery systems (DSDSs) in recent decades, and their stimuli-responsive drug release has usually been controlled by the conjugations between the drug molecules, including the stimuli (pH or redox) and responsive sensitivity. Here, an acid-triggered dimeric prodrug of doxorubicin (DOX) was synthesized by conjugating two DOX molecules with an acid-labile ketal linker. It possessed high drug content near the pure drug, while the premature drug leakage in blood circulation was efficiently suppressed. Furthermore, its aggregation structures were controlled by fabricating nanomedicines via different approaches, such as fast precipitation and slow self-assembly, to regulate the drug release performance. Such findings are expected to enable better anti-tumor efficacy with the desired drug release rate, beyond the molecular structure of the dimeric prodrug.

Chitosan-Derived Nanocarrier Polymers for Drug Delivery and pH-Controlled Release in Type 2 Diabetes Treatment.

Diabetes, particularly Type 2 Diabetes Mellitus (T2DM), is a chronic metabolic disorder with high and increasing global prevalence, characterized by insulin resistance and inadequate insulin secretion. Despite advancements in novel drug delivery systems, widespread and systematic treatment of advanced glycation end products (AGEs) remains challenging due to issues like drug toxicity, low water solubility, and uncontrolled release. Thus, developing nanoplatforms with controlled release capabilities has become a major research focus. Due to its excellent biocompatibility and drug delivery properties, chitosan has attracted considerable attention as a typical biopolymer. In this study, we designed and synthesized an intelligent fluorescence-pH sensitive nanopolymer material using chitosan. We loaded drug 1 and chromium phthalocyanine (CrPc) into folic acid-conjugated carboxymethyl chitosan (FA-CMCS) nanocarriers, forming FA-CMCS@1-CrPc. Comprehensive characterization of FA-CMCS@1-CrPc was conducted using Fourier transform infrared spectroscopy (FTIR), scanning electron microscopy (SEM), transmission electron microscopy (TEM), thermal gravimetric analysis (TGA), and gas adsorption analysis (BET). The results indicate that the nanomaterial was successfully synthesized and exhibits excellent specific surface area, biocompatibility, and fluorescence response. Further research revealed that FA-CMCS@1-CrPc not only achieved controlled drug release but also could regulate drug release by adjusting pH. Additionally, due to its strong fluorescence performance, the nanomaterial demonstrated higher detection sensitivity, especially for monitoring the release of 5% trace drugs. An in vitro model of insulin-resistant cells was established to evaluate the effects of the drug delivery system on glucose degradation and AGE-RAGE regulation, providing a foundation for the development of new T2DM drugs.

Comparative Analysis with Data Prediction of Non-linear Radiative Nano Second-Grade and Newtonian Fluid in Presence of Sinusoidal Magnetic Force

This study aims to enhance the comprehension of the fundamental fluid behavior by comparing Newtonian fluid with second-grade fluid under the influence of periodic magnetic fields, nonlinear radiative nanomaterial, and a porous stretched surface featuring a heat source. The governing equations' dimensionless forms are generated by applying the proper transformations, and the explicit finite difference (EFD) method is used to solve the numerically-derived solution while carefully maintaining stability and convergence standards. The results include velocity, heat, and mass transfer oscillation profiles; streamlines, and isothermal lines. Nusselt and Sherwood numbers are correlated with different factors according to tabular studies, and data prediction and regression are done using graphical representations. This study revealed that, in contrast to Newtonian fluid, second-grade fluid flow elevates velocity profiles with variations in chemical reaction parameters and mass Grashof numbers. Conversely, the thermal non-linear radiation and heat source in second-grade fluid particles effectively enhance the temperature field, although the temperature increase is more pronounced in Newtonian fluid compared to second-grade fluid. Also, second-grade fluid flow exhibits a lower mass transmission rate but higher stress sharing and heat transmission rates compared to Newtonian fluid flow. The implications of this research may impact prostate cancer treatment, as cancer patients have already benefited from the use of magnetic fields to regulate drug release from nanoparticles. Although the greater stress sharing and heat transmission rates may be used for targeted therapy, the lower mass transmission rate raises the possibility of benefits in controlled release scenarios.

Effect of mPEG-PLGA on Drug Crystallinity and Release of Long-Acting Injection Microspheres: In Vitro and In Vivo Perspectives.

Traditional progesterone (PRG) injections require long-term administration, leading to poor patient compliance. The emergence of long-acting injectable microspheres extends the release period to several days or even months. However, these microspheres often face challenges such as burst release and incomplete drug release. This study aims to regulate drug release by altering the crystallinity of the drug during the release process from the microspheres. This research incorporates methoxy poly(ethylene glycol)-b-poly(lactide-co-glycolide) (mPEG-PLGA) into poly(lactide-co-glycolide) (PLGA) microspheres to enhance their hydrophilicity, thus regulating the release rate and drug morphology during release. This modification aims to address the issues of burst and incomplete release in traditional PLGA microspheres. PRG was used as the model drug. PRG/mPEG-PLGA/PLGA microspheres (PmPPMs) were prepared via an emulsification-solvent evaporation method. Scanning electron microscopy (SEM), powder X-ray diffraction (PXRD), and differential scanning calorimetry (DSC) were employed to investigate the presence of PRG in PmPPMs and its physical state changes during release. The addition of mPEG-PLGA altered the crystallinity of the drug within the microspheres at different release stages. The crystallinity correlated positively with the amount of mPEG-PLGA incorporated; the greater the amount, the faster the drug release from the formulation. The bioavailability and muscular irritation of the long-acting injectable were assessed through pharmacokinetic and muscle irritation studies in Sprague-Dawley (SD) rats. The results indicated that PmPPMs containing mPEG-PLGA achieved low burst release and sustained release over 7days, with minimal irritation and self-healing within this period. PmPPMs with 5% mPEG-PLGA showed a relative bioavailability (Frel) of 146.88%. In summary, adding an appropriate amount of mPEG to PLGA microspheres can alter the drug release process and enhance bioavailability.

Hydrogel-Based Drug Delivery Nanosystems for the Treatment of Brain Tumors: A Systematic Review

The limitations and negative effects of current therapeutic techniques for brain tumors necessitate the selection of alternative therapeutic options. Therapeutic hydrogel systems that are monitored by magnetic resonance imaging (MRI) are one alternative for neurosurgical treatment of brain tumors that does not need any invasive procedures. There is a significant deal of potential for the treatment of brain tumors that can be attributed to the specific physical and chemical properties that hydrogels possess. The ability to encapsulate therapeutic molecules, provide regulated and sustained drug release, and successfully pass the blood-brain barrier are some of the properties that are included in this category. By combining hydrogel systems with magnetic resonance imaging (MRI) capabilities, it is possible to design therapeutic approaches that provide regulated release of therapeutic medications and real-time monitoring possibilities. Despite the fact that surgical resection is still extremely important, there is a growing demand for alternatives that can supplement or even replace it. Within the scope of this narrative review, the therapeutic hydrogel systems that are monitored by magnetic resonance imaging (MRI) will be evaluated to determine their potential for the non-surgical treatment of brain tumors.

Biocompatability chitosan /Aloe barbadensis miller loaded moxifloxacin composite film: A multifunctional bio-platform for the treatment of breast cancer

Binary biodegradable polymers exhibit excellent functional behavior but the limited mechanical integrity for regulating drug release within the polymeric matrix, hence it needs modification in the polymer network to overcome the limitations. The compatibility of bipolymer blends with incorporation of drugs within their matrices to enhance physicochemical properties and drug delivery kinetics have garnered significant attention in recent research. Herein, we examine the influence of the film produced by the casting technique, which consists of chitosan (CS) and Aloe barbadensis miller (ABM) gel, embedded with moxifloxacin (MoF), on attenuating the breast cancer (MCF-7) cell line. Firstly, spectroscopy confirmed the intermolecular interactions between the matrixes and the grafting of components. Notably, the addition of ABM produces significant changes in the film properties, such as decreased elongation. The pivotal moment resulted in the generation of more stable films that displayed enhanced stability at temperatures below 200 °C, as confirmed by TGA analysis. Additionally, film surfaces exhibiting strong water affinity were found to be more favorable for cell adhesion, subsequently hindering the proliferation of compromised cells. Remarkably, the In vitro cytotoxicity study showed the antibiotic-grafted CS-ABM/MoF scaffolds exhibited high cell adhesion and improved the rate of cell death was higher compared to other films. The antibacterial activity against S. aureus and E. coli results strongly suggests the enhanced antibiotic ability of the polymeric CS- ABM/MoF film. These results findings indicated that the CS- ABM/MoF scaffolds' hydrophilic surface significantly contributes to the improved cell adhesion efficiently used for biomedical applications.

Hollow-structured covalent organic framework decorated with FA-PEG: A biocompatible nanocarrier for targeted and pH-responsive release of doxorubicin

Hollow nanostructures hold great promise for drug delivery applications due to their considerable capabilities for efficient drug encapsulation alongside distinct physicochemical attributes. Herein, an imine-linked hollow nanosphere covalent organic framework (COF) with high surface area and well-structured porosity was developed serving as a versatile drug delivery system (DDS) to achieve targeted and effective delivery of doxorubicin (DOX) as a chemotherapeutic agent. The production of COF hollow nanoparticles included the use of a heterogeneous nucleation and growth method, followed by the subsequent encapsulation of DOX. Following this, the nanoparticles underwent functionalization with folate-poly (ethylene glycol)-amine (FA-PEG) using a bonding defect strategy. An in vitro cytotoxicity assay and flow cytometry study against FR-negative HEK293 and FR-positive MCF7 cells were performed, revealing that FA-PEG-functionalized HCOF exhibited a unique targeting effect on cancer cells, surpassing the impact of DOX@HCOF on FR-positive MCF7 cancer cells. Additionally, the hollow architecture of the COF is engineered to undergo disintegration selectively under conditions of cancer cell pH, facilitating the comprehensive release of DOX. The pH-responsive and tumor-targeted attributes of the DOX@HCOF-PEG-FA open new avenues for incorporating structural engineered HCOFs as a promising drug carrier capable of regulating drug release and augmenting therapeutic efficacy.

Nanogels as Drug Delivery Carrier: A Narrative Review on Formulation Techniques, Characterization, Applications, and Patents.

Under the umbrella of targeted drug delivery systems, several techniques are unleashed in the market that allow a drug or other pharmacologically active material to be delivered to the target cell to treat a condition or health problem. The improvement of the pharmaceutical delivery systems' effectiveness, safety, and stability is accomplished through the Formulation of the nano-gel-based delivery system. Nanogels are aqueous dispersions of submicronsized, three-dimensional, strongly cross-linked networks of hydrophilic polymers that are inflated by water. Through a variety of delivery routes, such as oral, pulmonary, nasal, parenteral, and intraocular, an active pharmaceutical agent or therapeutic agent with a high or low molecular weight can be easily encapsulated into nanogels. Nanogels have been researched as drug delivery systems due to their beneficial qualities, such as biocompatibility, high stability, flexible particle size, drug loading capacity, and potential surface modification for active targeting by attaching ligands that recognize cognate receptors on target cells or tissues. By responding to internal or external stimuli, including pH, temperature, light, and redox, nano gels can be made to be stimulus-responsive, allowing for regulated drug release. Thus, in the fact of said characteristics' of nano gels, this review manuscript aims to provide an overview of characterization, evaluation, formulation technique, recent applications, and patents of nano gels.

Luteolin-incorporated fish collagen hydrogel scaffold: An effective drug delivery strategy for wound healing

In clinical practice, wound care has always been challenging. Hydrogels play a key role in facilitating active wound recovery by absorbing exudates, maintaining moisture, and alleviating pain through cooling. In this study, type I collagen was isolated from the skin of crucian carp (Carassius carassius) and verified by amino acid analysis, FTIR, and SDS-PAGE. By adopting a new approach, luteolin was added to collagen hydrogels in situ after being dissolved in an alkaline solution. XRD and SEM confirmed the luteolin was incorporated and entirely distributed throughout the hydrogel. The plastic compression improved the young's modulus of hydrogel to 15.24 ± 0.59 kPa, which is adequate for wound protection. The drug loading efficiency was 98 ± 1.47 % in the selected formulation. The luteolin-incorporated hydrogel enabled regulated drug release. We assessed the cytotoxicity using MTT and live-dead assays, as well as examined the hemocompatibility to determine the biocompatibility of the hydrogel. In vivo experiments showed that the hydrogel with luteolin had the highest wound closure rate (94.01 ± 2.1 %) and improved wound healing with granular tissue formation, collagen deposition, and re-epithelialization. These findings indicate that this efficient drug delivery technology can accelerate the process of wound healing.

Surface Modification of Mesoporous Silica Nanoparticles for Application in Targeted Delivery Systems of Antitumour Drugs.

The problem of tumour therapy has attracted the attention of many researchers for many decades. One of the promising strategies for the development of new dosage forms to improve oncology treatment efficacy and minimise side effects is the development of nanoparticle-based targeted transport systems for anticancer drugs. Among inorganic nanoparticles, mesoporous silica deserves special attention due to its outstanding surface properties and drug-loading capability. This review analyses the various factors affecting the cytotoxicity, cellular uptake, and biocompatibility of mesoporous silica nanoparticles (MSNs), constituting a key aspect in the development of safe and effective drug delivery systems. Special attention is paid to technological approaches to chemically modifying MSNs to alter their surface properties. The stimuli that regulate drug release from nanoparticles are also discussed, contributing to the effective control of the delivery process in the body. The findings emphasise the importance of modifying MSNs with different surface functional groups, bio-recognisable molecules, and polymers for their potential use in anticancer drug delivery systems.